wegovy

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access despite strong market demand. What Happened: The medications cost around $500 monthly for uninsured patients, while insured coverage remains inconsistent...

Telehealth darling Hims & Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable. But is the plunge a chance to swipe right on the dip, or should investors ghost the stock altogether? The high...

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant industry’s long-term growth. The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on...

Eli Lilly and Company’s (NYSE:LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE:NVO) Wegovy in a 72-week head-to-head trial. What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7...

Novo Nordisk A/S (NYSE:NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables. What Happened: On Wednesday, during Novo’s first quarter earnings call...

Hims & Hers Health Inc. (NYSE:HIMS) is suddenly looking like the hottest prescription in town – up 220% in the past year and turning heads with a bold new partnership that might just reshape digital healthcare. The company announced a long-term collaboration with pharmaceutical...

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European Union and China. On Thursday, the Dow Jones Industrial Average fell 1.3% to close at 39,142.23....

Weight loss drugs have taken the world by storm and saw strong demand for the companies selling them. A new study shows that despite the increase usage of weight loss drugs, obesity is still on the rise and could hit staggering numbers in the next 25 years. What Happened: The public support of...

Amgen Inc. (NASDAQ:AMGN) has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the company’s pursuit to break into the growing market for obesity drugs. What Happened: The MARITIME program, the drug...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with the Senate Finance Committee. While Kennedy’s tone in each back-and-forth varied, depending on the senator, it was...

An endorsement of a weight-loss drug by world's richest man Elon Musk could prove beneficial in the battle between two health care companies seeing revenue growth and soaring stock prices as interest in weight-loss drugs grows. What Happened: A post from Musk on Christmas shared his latest take on...

Novo Nordisk A/S (NYSE:NVO) saw its stock crater nearly 20% on Friday, eyeing its worst single-day drop since April 2002, after releasing underwhelming weight-loss trial results for its much-hyped obesity drug, CagriSema. To put the move in perspective, the only steeper plunge in the Danish pharma...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's (NASDAQ:AMGN) new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/...

The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordisk A/S (NYSE:NVO) has faced backlash for the steep prices of Wegovy and Ozempic, two popular drugs...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects. What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly & Co...